ClinicalTrials.gg
CompletedNCT07722286Updated Jul 23, 2026

Relapse and Functional Outcomes in Anti-LGI1 Encephalitis

An observational study in Autoimmune Encephalitis, LGI1 Encephalitis and Limbic Encephalitis, sponsored by Shen Chun-Hong. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Shen Chun-Hong · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
112
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Autoimmune Diseases of the Nervous System with a site in China — 18 open to participants now, 20 under way, 3 of them phase 3. Autoimmune Diseases of the Nervous System · China.

Enrollment
10th of 13
112 · median 300
Started
2015
the only one that year
Observational
13 of 26
9 open now
Registered
20th of 26
by date
Lead sponsor
3 of 26
Shen Chun-Hong

Among the 26 studies in Autoimmune Diseases of the Nervous System with a site in China, this one is the 10th largest by enrollment of the 13 observational ones that give a count, is the only one that started in 2015, is one of 13 observational ones, and was the 20th registered.

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

Browse Autoimmune Diseases of the Nervous System studies →

Open to participants now

18 of the 26 studies in Autoimmune Diseases of the Nervous System with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Autoimmune Diseases of the Nervous System with a site in China, or all of them as a file.
02

Study summary

This study focuses on a rare brain disease called anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. In this condition, the body's immune system mistakenly attacks a protein in the brain, which can cause problems with memory, thinking, behavior, and seizures. While most patients get better with initial treatments, some continue to have long-term symptoms or experience a return of the disease (called a "relapse") months or years later. The goal of this study is to understand how often these relapses and long-term problems happen and to identify which patients are most at risk.

The investigators will look back at the medical records of patients diagnosed with anti-LGI1 encephalitis at five major hospitals in Eastern China. The information about their symptoms, the treatments they received and how they recovered over time are obtained. Then, the investigators will analyze this information to find out what factors are linked to having a relapse or a poor long-term recovery.

By understanding the risks for relapse and poor outcomes, doctors can better identify which patients need closer monitoring and more long-term treatment strategies. The results of this study will help create better guidelines for managing patients with this disease after their initial recovery, aiming to improve their quality of life in the long run.

Read the detailed description
  1. Study Background:

    Anti-LGI1 encephalitis is an autoimmune disorder where the body produces antibodies that attack the brain, leading to symptoms like memory loss, psychiatric issues, and seizures. Initial treatments with immunotherapy (like steroids) are effective for most patients. However, a significant number of patients are left with lasting neurological problems, and some experience a return of the disease (relapse) after a period of improvement. The rates of relapse and poor long-term outcomes reported in previous studies vary widely, and it is not clear which patients are most vulnerable. Furthermore, the best strategy for long-term treatment after the initial phase to prevent relapses is not well-established.

  2. Study Objectives

    This study aims to:

    • Describe how often patients with anti-LGI1 encephalitis experience a relapse of the disease.
    • Assess their long-term functional recovery.
    • Identify patient characteristics, symptoms, or treatment factors that may increase the risk of relapse or poor recovery.
  3. Data Collection

    Data was gathered from electronic medical records and, when necessary, follow-up phone interviews. The information collected includes:

    • Patient Demographics: Age, sex.
    • Initial Illness: Symptoms at diagnosis, severity of the disease.
    • Test Results: Findings from brain scans (MRI), brain wave tests (EEG), antibody levels and other relevant information.
    • Treatments: Primarily types and durations of immunotherapy received (e.g., steroids, intravenous immunoglobulin, and maintenance immunosuppressants).
  4. Outcome Definitions

    • Relapse: The return of new or worsening symptoms after the patient had been stable or improving for at least 3 months.
    • Functional Outcome: The patient was largely independent in their daily activities at the last follow-up.
03

Conditions studied

  • Autoimmune Encephalitis
  • LGI1 Encephalitis
  • Limbic Encephalitis

Keywords

  • Anti-LGI1 Encephalitis
  • Relapse
  • Seizure recurrence
  • Risk factor
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients at five tertiary medical centers from four cities in Eastern China (Second Affiliated Hospital of Zhejiang University School of Medicine, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Shaoxing People's Hospital, Ningbo Medical Center Lihuili Hospital, and Huzhou Third People's Hospital)

Eligibility criteria

Inclusion Criteria:

  1. Characteristic presentations of anti-LGI1 encephalitis;
  2. LGI1-immunoglobulin G (IgG) positivity in serum and/or cerebrospinal fluid (CSF) by fixed cell-based assay (Euroimmun, Lübeck, Germany)
  3. follow-up ≥ 18 months after initial immunotherapies
  4. exclusion of alternative diagnoses

Exclusion Criteria:

  1. presence of coexisting neural autoantibodies
  2. history of central nervous system (CNS) infections, severe neurological or primary psychiatric disorders
  3. no prior use or lack of immunotherapy
  4. insufficient follow-up data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
112 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Relapse

    the presence of new or worsening clinical features after at least 3 months of stability or improvement

    Time frame: Through study completion, with the last follow-up date in January 2026

Secondary outcomes

  1. Functional outcomes

    an mRS score at the last follow-up ≤ 2 indicated good outcome, while an mRS score \> 2 indicated poor outcome

    Time frame: Through study completion, with the last follow-up date in January 2026

07

Study locations

1 site
  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Jan 2026, 132 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2025
First posted
Jul 23, 2026
StartActual
Jan 1, 2015
Primary completionActual
Jan 1, 2026
CompletionActual
Jan 1, 2026
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07722286
Lead sponsor
Shen Chun-Hong
Collaborators
Sir Run Run Shaw Hospital, Shaoxing People's Hospital, Ningbo Medical Center Lihuili Hospital, Huzhou Third People's Hospital
Responsible party
Shen Chun-Hong (Associate Senior Doctor, Second Affiliated Hospital, School of Medicine, Zhejiang University) — Sponsor-investigator
First posted
Jul 23, 2026
Start date
Jan 1, 2015
Primary completion
Jan 1, 2026
Completion
Jan 1, 2026
Last update
Jul 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion